Global Leaders in Biologics
History & Timeline
A History of Innovation
Since the company’s founding, RTI Biologics Inc. has remained at the forefront of a changing industry, becoming one of the largest processors of biologic implants and a global leader in tissue-based innovations.
Regeneration Technologies Inc. began operations in February 1998, when the University of Florida Tissue Bank transferred its allograft processing operations, related equipment and technologies, distribution arrangements and research and development activities to RTI. Ten years later, on Feb. 27, 2008, RTI merged with Tutogen Medical Inc., to create RTI Biologics Inc. – one of the leading providers of sterile biological implants for surgeries around the world.
Shaping the future, changing lives
As in all areas of science, research and development drive every advancement in regenerative medicine. To fund the research that enabled RTI to develop new and safer solutions in tissue transplantation, RTI completed an initial public offering in August 2000 and began trading on the NASDAQ exchange under the symbol RTIX. The funding from the IPO allowed RTI to improve its facilities and to develop improved processes and implants.
Commitment to patient safety
In March 2000, RTI made history in the allograft industry by developing BioCleanse®, a low-temperature chemical sterilization process that inactivates or removes bacteria, fungi, spores and viruses from tissue without compromising the biocompatibility or structural integrity of the tissue.
RTI opened its state-of-the-art facility in 2002 to better ensure the safety and quality of its implants. Two years later, RTI implemented BioCleanse for sterilization of soft tissue implants.
Today, RTI employs multiple sterilization processes wherever possible to better protect recipients from the risk of donor-to-recipient disease transmission.
RTI is leading the evolution of biologics again by offering a bovine based biological matrix, providing surgeons an expanded supply of safe, sterile tissue for their patients.
Going forward, the broader reach resulting from the merger of RTI and Tutogen, combined with an ongoing investment in research and development, ensures RTI innovations will continue to evolve the field of regenerative medicine, enhance the lives of patients and put the extraordinary gifts of tissue donations to their best use.